“Our Actions Reflect Our Values”                -Novo Nordisk                    Presented By:                   Shruti Dw...
Introduction• Company: Novo Nordisk®• Drug Name: NN1952 (No Name Assigned)• Indication: Oral replacement therapy for patie...
Facts• More than 50% of all diabetics who must use insulin injections  to manage their disease miss injections on a regula...
Our PlanTarget: Social Media  Focus: Exposure
Goal
Website focused on Diabetics• We are launching an online support program for diabetes  patients, dubbed Cornerstone4care t...
Diabetes APP•   We plan to develop a software for Diabetics    which allows them to record, store, and    analyze informat...
Social media
Social media
Upcoming SlideShare
Loading in...5
×

Social media

293

Published on

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
293
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
1
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide
  • http://www.novonordisk.com/images/about_us/changing-diabetes/frontimage.jpghttp://www.novonordisk-us.com/documents/article_page/document/Our_Values.asp
  • http://clinicaltrials.gov/ct2/show/NCT01028404
  • http://www.diabeticlive.com/diabetes-101/the-reasons-behind-missed-injections/#.Ts3A6rIk61c
  • http://www.mmm-online.com/novo-nordisk-refreshes-diabetes-online-presence-with-cornerstones4care/article/194553/
  • http://www.cornerstones4care.com/Index.aspx
  • http://forecast.diabetes.org/magazine/features/2011-software-applications-controlling-diabetes
  • Social media

    1. 1. “Our Actions Reflect Our Values” -Novo Nordisk Presented By: Shruti Dwivedi Abdul Al-Jazairi Roohee Peerzada
    2. 2. Introduction• Company: Novo Nordisk®• Drug Name: NN1952 (No Name Assigned)• Indication: Oral replacement therapy for patients with Type 1 & Type 2 diabetes• Fast-acting oral insulin analogue. First phase 1study completed during the fourth quarter of 2010. – The first drug of its class – Potential Blockbuster – Novo Nordisk has a licensing deal with Merrion Pharmaceuticals – NN is using GIPET® technology by Merrion Pharms to develop the oral formulation – Deal: Merrion will get $54M for the first product to be launched – Have already received $2M as the drug progressed to Phase II
    3. 3. Facts• More than 50% of all diabetics who must use insulin injections to manage their disease miss injections on a regular basis.• Why would someone intentionally bypass the use of medication that can help them in their personal health care?• The two of the most common reasons : – I am embarrassed – It is painful
    4. 4. Our PlanTarget: Social Media Focus: Exposure
    5. 5. Goal
    6. 6. Website focused on Diabetics• We are launching an online support program for diabetes patients, dubbed Cornerstone4care that promises patients one-stop shopping for diabetes information and product information• They can also get recipes, calculate nutritional values, connect with other patients and get daily action plans tailored to their lifestyle and information needs, along with strategies for dealing with special situations like travel.• The site focuses on four “cornerstones” of diabetes control – checking blood sugar, eating healthy, exercising and taking medications
    7. 7. Diabetes APP• We plan to develop a software for Diabetics which allows them to record, store, and analyze information electronically, all in the palm of your hand.• Features: – This app lets you record blood glucose levels and note the time of day—such as “before breakfast” or “during activity.” – You can view trend graphs, interact in the forums, and record insulin injections, exercise, and food eaten. – You can also sync your phone to an online account to manage your data on our website. – Easily downloadable to cell phones and computers – Compatible with almost every data network
    1. A particular slide catching your eye?

      Clipping is a handy way to collect important slides you want to go back to later.

    ×